
In today’s briefing:
- Bain To Launch an MBO for Aircraft Maintenance Co JAMCO (7408) ¥1800 Is Too Cheap
- Henlius (2696 HK): LVC Sits On A Blocking Stake. And Me (Maybe) Eating Humble Pie
- Henlius (2696 HK): Hurtling Towards a Likely Deal Break
- Tokyo Metro (9023 JP): Index Inclusions – Light at the End of the Tunnel
- KRX H1 SSF Reshuffle: Play Setup from Last Round’s Learning Curve
- Foshan Haitian Flavouring & Food (603288 CH): Index Inclusion Post H-Share Listing
- Samsung Electronics’ Key Inflection Point: Lee Jae-Yong’s Final Appeal Ruling on February 3
- JAMCO (7408 JP): Bain’s Tender Offer Is Light but Likely a Done Deal
- AVJennings (AVJ AU): Ho Bee’s Superior Proposal
- Ahead of Macquarie’s PUSU Deadline

Bain To Launch an MBO for Aircraft Maintenance Co JAMCO (7408) ¥1800 Is Too Cheap
- Bain is buying out JAMCO (a long time ago called Itochu Aircraft Maintenance) from Itochu, ANA, Bain’s own portfolio company, and the public. It’s an expected deal. A done deal.
- It is being done too cheaply. The price is 6x next year’s expected EBIT. This year expected ROE is 22%. Next year could be double that.
- And the company has more in non-operating financial assets than its net equity. And a lot of really old land assets are not marked up. Just a shame.
Henlius (2696 HK): LVC Sits On A Blocking Stake. And Me (Maybe) Eating Humble Pie
- I was wrong. Loyal Valley Capital (LVC) have stopped buying Shanghai Henlius (2696 HK) – or have not bought since reaching a blocking stake of 7.8295% on the 9th January.
- LVC could either use that stake as leverage to negotiate with the Offeror on the scrip terms. Or blow up the deal and pick up shares after the deal breaks
- OR perhaps, as per my initial impression, LVC tenders. And they may still do that. It should be this straightforward; but the fact that it is not raises questions.
Henlius (2696 HK): Hurtling Towards a Likely Deal Break
- The vote on Fosun Pharma’s HK$24.60 offer for Shanghai Henlius Biotech (2696 HK) is on 22 January. The gross spread has ballooned to 21.8%, which suggests a deal break.
- I previously stated that LVC’s trading behaviour over the coming days will indicate its voting intentions. Unfortunately, this behaviour suggests a high likelihood of blocking the vote.
- Fosun Pharma has two potential options to secure LVC’s backing: increase the share alternative cap or introduce a rollover option. Both have challenges and are, therefore, not viable options.
Tokyo Metro (9023 JP): Index Inclusions – Light at the End of the Tunnel
- Tokyo Metro (9023 JP) listed on 23 October and was added to the TSE Tokyo Price Index TOPIX (TPX INDEX) at the close on 28 November.
- Tokyo Metro (9023 JP) was not expected to be added to one global index (it was not added), while it was expected to be added to the other (and missed).
- The stock could be added to one global index in February (its close!) and to the other in June (pretty much a sure thing).
KRX H1 SSF Reshuffle: Play Setup from Last Round’s Learning Curve
- Last time, price action showed up a week early, suggesting market makers are getting ahead, likely due to learning effects.
- This round’s a letdown—no KOSDAQ names and fewer plays. Still, lower-volume KOSPI names showed solid price action correlation in the last reshuffle.
- This round, focus on low-volume KOSPI names, enter 5 days before the listing, and exit just before it drops, using the learning curve from the last reshuffle.
Foshan Haitian Flavouring & Food (603288 CH): Index Inclusion Post H-Share Listing
- Foshan Haitian Flavouring & Food (603288 CH) has filed for a listing on the HKEX (388 HK) and reports indicate that the raise will be at least US$1.5bn.
- In line with the Midea Group (300 HK) and S.F. Holding (6936 HK) H-share listings, the discount on the H-shares could be in the 20-25% range.
- The stock will not get Fast Entry to any indices but there should be inclusions at subsequent rebalances, especially once the cornerstone investor lock-up expires.
Samsung Electronics’ Key Inflection Point: Lee Jae-Yong’s Final Appeal Ruling on February 3
- Some speculate Samsung might delay the value-up announcement until after the February 3 ruling, using it strategically to influence the verdict and align with the appeal’s outcome.
- Market chatter even surrounds Samsung’s HBM test delays with NVIDIA, with some linking it to Lee Jae-yong’s February 3 appeal ruling—though it seems more like speculative conspiracy.
- If Lee Jae-yong wins his appeal on February 3, it could trigger key events like value-up disclosure and HBM pass, significantly impacting Samsung’s short-term price action and positions.
JAMCO (7408 JP): Bain’s Tender Offer Is Light but Likely a Done Deal
- Jamco Corp (7408 JP) announced a preconditional tender offer from Bain Capital at JPY1,800 per share, a 27.8% premium to the last close.
- The offer, which is preconditional on regulatory approvals and will open in mid-February, is attractive compared to historical trading ranges.
- On the other hand, the offer is light as it is below the midpoint of the IFA DCF valuation range. However, the modest required acceptance rate suggests a done deal.
AVJennings (AVJ AU): Ho Bee’s Superior Proposal
- Back on the 28th November, AVJennings Ltd (AVJ AU), a reputable home builder in Australia/New Zealand, entered into a deed granting the AVID consortium exclusive confirmatory due diligence.
- The AVID consortium, comprising Proprium Capital Partners and AVID Property Group, pitched an NBIO (by way of a Scheme) of A$0.67/share. Singapore’s SC Global (54.5% shareholder) was supportive.
- In what appeared to be clean deal, Ho Bee Land Ltd (HOBEE SP) then acquired a 5.39% stake on the 23rd December. Now they’ve made their own NBIO at A$0.70/share.
Ahead of Macquarie’s PUSU Deadline
- Macquarie’s final offer of 870 pence per share represents a 57% premium over Renewi’s November 27, 2024, closing price, valuing the company at approximately €1.06 billion.
- Macquarie secured irrevocable undertakings from major shareholders holding 15.1% of shares and aims to finalize the offer by January 23, 2025, pending due diligence.
- The offer aligns closely with Renewi’s intrinsic value, offering investors an attractive exit opportunity with a market-implied deal probability of 78.5%. Via Scheme, completion by end of March/early April.